The following policies were updated during the 2010-2011 AAHRPP re-accreditation process.
Name of Policy
No.
Organization Policy on Exempt Research
101.1
Organization Policy on Determination of “Human Subject Research” and Exempt Research
102.1
Organization Policy on HSPP Assurance of Compliance with DHHS Policy
103.1
Organization Statement of Commitment to the Principles Governing Human Subjects Research
103.3
Organization Policy on List of IRB Members
103.4
Organization Policy on Meeting Procedures
103.5
Organization Policy on Reporting
103.6(a)
Organization Policy on Reports of Unanticipated Problems Involving Risks to Participants or Others
103.6(b)
Organization Policy on Reporting Death of a JHM Research Participant
103.6(b)(i)
Organization Policy on Data and Safety Monitoring of Proposed Research
103.6(c)
Organization Policy on Investigator Non-Compliance
103.7
Organization Policy on Ancillary Reviews for Human Subject Research Studies
103.10(a)
Organization Policy on Assignment of IRB Review
103.10(b)
Organization Policy on Committee on Outside Interests (COI) and the JHM IRB
103.11
Organization Policy on Human Subjects Research Compliance Training
103.12
Organization Policy on Policy Development and Communication
103.18
Organization Policy on Pharmacy and Therapeutics Committee and JHM IRB
103.19
Organization Policy on Drug Use and Control in Clinical Investigations
103.19(a)
Organization Policy Investigational Drug Service (IDS) and OHSR
103.20
Organization Policy on Institutional Biosafety Committee (IBC) and the JHM IRB
103.22
Organization Policy on Principal Investigator Responsibilities
103.24(a)
Organization Policy on IRB Composition and OHSR Staff Qualifications
107.1
Organization Policy on Consultants
107.2
Organization Policy on Training and Evaluation of IRB Members and Chairs
107.3
Organization Policy on Quorum, Voting Status of IRB Alternate Members, and JHM IRB Member Attendance
108.1
Organization Policy on Responsibility for the Human Subjects Protection Program (HSPP)
109.1(a)
Organization Policy on IRB Authority to Review Research
109.1(b)
Organization Policy on IRB Actions
109.5
Organization Policy on Continuing Review of Approved Research
109.6(b)
Organization Policy on Expired JHM IRB Approval: Protocols and Consent Forms
109.7
Organization Policy on Monitoring the Consent Process and Research Procedures in Ongoing Research
109.8
Organization Policy on Expedited Review of Proposed Research
110.1
Organization Policy on Payment or Remuneration to Human Subjects
111.2
Organization Policy on Scientific Review
111.5
Organization Policy on Financial and Personal Conflict of Interest Policy for IRB Members
111.11
Organization Policy on Recruiting Study Subjects
111.13
Organization Policy on Institutional Review of IRB Approved Research
112.1
Organization Policy on Suspension or Termination of IRB Approved Research
113.1
Organization Policy on Cooperative Research and Multi-Center Studies
114.2
Organization Policy on IRB Records
115.1
Organization Policy on Protocol Record Retention Requirements for Investigators
115.2
Organization Policy on Informed Consent Process and Documentation
116.1
Organization Policy on Translation of Consent Documentation
116.3
Organization Policy on Review of Research Involving Prisoners
C304
Organization Policy on Clinical Investigations with FDA “Test Articles”
FDA 312/812
Organization Policy on Humanitarian Use Devices
FDA 814.1
Organization Policy on Planned Emergency Research and Requirements for Waiver of Consent in Planned Emergency Research 21 CFR 50.24; DHHS Emergency Research Consent Waiver
PER 1
Organization Policy on Sponsor Responsibilities
ORA.1
Organization Policy on Maryland State Law Requirements: Maryland House Bill No. 917 (Hubbard Act)
SL1
Organization Policy on Pathology Department Activities to Establish and Verify Laboratory Performance Specifications
PATH.1
FederalWide Assurances
U.S. Dept. Health & Human Services, Office for Human Research Protections (OHRP)
U.S. Food and Drug Administration